NorthEdge, a private equity firm, invested in Torbay Pharmaceuticals, a sterile injectable contract manufacturer and license holder, to support its next phase of international growth, after purchasing it from Torbay and Devon NHS Foundation Trust.

Torbay has seen an increasing demand for its commercial-scale sterile injectable fill/finish capabilities. The business supplies healthcare organizations and pharmaceutical companies throughout the UK and internationally.

With the investment, Torbay plans to strengthen its capabilities and significantly expand its reach in North America, while continuing to invest in its team at its UK headquarters in Paignton, Devon.

Further North American market expansion offers a range of commercial opportunities for Torbay. To support this, the investment will facilitate the growth of Torbay’s team, greater automation of inspection and packaging processes and strengthen its plastic vial capabilities.

The investment will also ensure Torbay is well-positioned to meet evolving regulatory requirements in both the U.S. and Europe. Torbay has also invested in a new high-speed filling line to support customer growth.

NorthEdge CEO Emma Rooth said, “From our earliest days supporting local hospitals, we have never lost sight of our primary goal which is to create quality medicines that deliver the very best outcomes for patients. This commitment will continue to drive everything we do at Torbay.”

Liz Davenport, CEO at Torbay, and Devon NHS Foundations Trust said, “We are justly proud of how Torbay Pharmaceuticals has grown from a backroom in Torbay Hospital in the 1970s to a sizable manufacturer. Over the years, the company has constantly grown and innovated to deliver an increasing volume and range of medicines, while supporting local jobs and the NHS.”

Ray Stenton, Managing Partner at NorthEdge added, “We are delighted to be supporting Emma and the Torbay team on the next phase of their journey. This investment will allow management to accelerate the growth of the business, which will further improve patient outcomes nationally and internationally.”